Clinical Trial Priority List Advocated By CMS Coverage Chief, AHRQ Director
This article was originally published in The Gray Sheet
Executive Summary
The Institute of Medicine should develop a list of "knowledge gaps" to help establish priorities for public and private funders of clinical trials, according to an editorial by CMS and AHRQ staffers in the Sept. 24 Journal of the American Medical Association.
You may also be interested in...
Devices Escape Comparative Effectiveness Study Focus With Limelight On Rx
The device industry has once again received a reprieve from comparative effectiveness trial provisions as policymakers remain centered on controlling pharmaceutical costs
Devices Escape Comparative Effectiveness Study Focus With Limelight On Rx
The device industry has once again received a reprieve from comparative effectiveness trial provisions as policymakers remain centered on controlling pharmaceutical costs
Cost-Effectiveness Trials Needed To Control New Technology Costs – Panel
Leveraging resources to conduct "practical clinical trials" that gauge a technology's benefit will become increasingly necessary as new technologies continue to drive up healthcare costs, according to Agency for Healthcare Research & Quality Director Carolyn Clancy, MD